Claes Ohlsson Selected Research

Dihydrotestosterone (Androstanolone)

5/2022	High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice.
12/2019	Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome.
1/2018	Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.
4/2015	The androgen receptor confers protection against diet-induced atherosclerosis, obesity, and dyslipidemia in female mice.
1/2013	Resveratrol is not as effective as physical exercise for improving reproductive and metabolic functions in rats with dihydrotestosterone-induced polycystic ovary syndrome.
11/2007	Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men.
4/2006	Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Claes Ohlsson Research Topics

Disease

34	Osteoporosis 01/2021 - 01/2004
25	Obesity 01/2021 - 01/2002
23	Neoplasms (Cancer) 05/2022 - 07/2004
23	Inflammation (Inflammations) 01/2022 - 07/2003
21	Osteoporotic Fractures 01/2022 - 08/2010
20	Arthritis (Polyarthritis) 01/2021 - 01/2004
19	Body Weight (Weight, Body) 01/2022 - 08/2003
17	Prostatic Neoplasms (Prostate Cancer) 05/2022 - 02/2006
14	Rheumatoid Arthritis 01/2021 - 01/2003
13	Insulin Resistance 06/2022 - 12/2002
13	Bone Resorption 01/2020 - 06/2004
10	Cardiovascular Diseases (Cardiovascular Disease) 02/2022 - 09/2010
8	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 11/2020 - 02/2010
7	Atherosclerosis 06/2016 - 10/2004
6	Myocardial Infarction 02/2022 - 01/2004
6	Experimental Arthritis 03/2016 - 01/2007
5	Type 2 Diabetes Mellitus (MODY) 01/2020 - 04/2011
5	Dyslipidemias (Dyslipidemia) 04/2015 - 01/2005
4	Hip Fractures (Intertrochanteric Fractures) 01/2020 - 04/2011
4	Postmenopausal Osteoporosis 11/2016 - 12/2014
4	Coronary Disease (Coronary Heart Disease) 05/2015 - 03/2012
3	Dementia (Dementias) 10/2022 - 09/2011
3	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2016
3	Hypertension (High Blood Pressure) 09/2014 - 01/2004
3	Metabolic Bone Diseases (Osteopenia) 05/2013 - 04/2004
2	Ischemic Stroke 02/2022 - 01/2021
2	Stroke (Strokes) 02/2022 - 07/2009
2	Anemia 01/2022 - 07/2014
2	Wrist Fractures 01/2022 - 01/2021
2	Heart Diseases (Heart Disease) 12/2021 - 06/2021
2	Osteomalacia 01/2021 - 07/2004
2	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2021 - 01/2014
2	Bone Diseases (Bone Disease) 01/2021 - 08/2015
2	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 04/2015
2	Gynecomastia 10/2020 - 08/2008
2	Disease Progression 10/2020 - 07/2003
2	Hyperandrogenism 10/2020 - 11/2011

Drug/Important Bio-Agent (IBA)

27	Estrogens (Estrogen)FDA Link 04/2022 - 03/2004
22	Testosterone (Sustanon)FDA Link 10/2022 - 04/2006
18	Estradiol (Delestrogen)FDA LinkGeneric 06/2022 - 06/2007
18	SteroidsIBA 01/2022 - 01/2009
17	AndrogensIBA 05/2022 - 06/2004
17	Insulin-Like Growth Factor I (IGF-1)IBA 12/2019 - 12/2002
12	Gonadal Steroid Hormones (Sex Hormones)IBA 02/2022 - 01/2003
10	LipidsIBA 01/2022 - 11/2007
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2007
8	Biological ProductsIBA 12/2021 - 05/2006
8	Vitamin D FDA LinkGeneric 12/2018 - 01/2011
7	Dihydrotestosterone (Androstanolone)IBA 05/2022 - 04/2006
7	Pharmaceutical PreparationsIBA 04/2022 - 04/2011
7	Insulin (Novolin)FDA Link 01/2022 - 05/2006
7	Hormones (Hormone)IBA 01/2022 - 01/2003
7	LeptinIBA 05/2020 - 01/2004
7	AdiponectinIBA 10/2017 - 06/2011
6	EnzymesIBA 04/2022 - 02/2013
6	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2006
6	Androgen Receptors (Androgen Receptor)IBA 01/2019 - 01/2009
6	Biomarkers (Surrogate Marker)IBA 11/2018 - 01/2004
6	Dehydroepiandrosterone (DHEA)IBA 01/2018 - 06/2009
6	CollagenIBA 07/2015 - 07/2004
5	Sex Hormone-Binding GlobulinIBA 10/2022 - 11/2011
5	MineralsIBA 01/2021 - 01/2009
5	Selective Estrogen Receptor Modulators (SERM)IBA 03/2016 - 10/2007
5	Interleukin-6 (Interleukin 6)IBA 09/2011 - 01/2002
4	enzalutamideIBA 05/2022 - 02/2016
4	Triglycerides (Triacylglycerol)IBA 01/2022 - 12/2014
4	Messenger RNA (mRNA)IBA 01/2021 - 12/2004
4	HDL CholesterolIBA 10/2019 - 11/2007
4	CalciumIBA 01/2018 - 01/2003
4	bazedoxifeneIBA 03/2016 - 12/2014
4	Raloxifene Hydrochloride (Evista)FDA Link 01/2016 - 10/2007
3	Estrone FDA Link 06/2022 - 06/2009
3	Androgen Antagonists (Antiandrogens)IBA 05/2022 - 01/2009
3	Phosphates (Orthophosphate)IBA 01/2022 - 07/2004
3	LDL CholesterolIBA 01/2022 - 10/2019
3	Fibroblast Growth Factor-23IBA 01/2022 - 07/2004
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 03/2007
3	CadmiumIBA 01/2021 - 04/2016
3	Aromatase (CYP19)IBA 01/2021 - 05/2013
3	C-Reactive ProteinIBA 10/2019 - 02/2014
3	GlucocorticoidsIBA 01/2019 - 01/2015
3	CytokinesIBA 01/2018 - 01/2003
3	Growth Hormone (Somatotropin)IBA 10/2016 - 10/2004
3	CholesterolIBA 06/2016 - 04/2015
3	LasofoxifeneIBA 03/2016 - 12/2014
3	AntigensIBA 07/2014 - 01/2005
3	Estrogen Receptor alphaIBA 07/2014 - 06/2007
3	Dexamethasone (Maxidex)FDA LinkGeneric 06/2011 - 01/2005
3	OsteocalcinIBA 03/2010 - 11/2004
3	Collagen Type II (Type II Collagen)IBA 02/2010 - 01/2005
3	salicylhydroxamic acid (SHAM)IBA 02/2010 - 01/2005
2	Androstenedione (4 Androstene 3,17 dione)IBA 06/2022 - 06/2009
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 07/2003
2	Hydrocortisone (Cortisol)FDA LinkGeneric 06/2021 - 09/2011
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2007
2	AntibodiesIBA 01/2020 - 02/2013

Therapy/Procedure

10	Therapeutics 01/2019 - 10/2007
7	Castration 05/2022 - 01/2009
6	Hormone Replacement Therapy (Therapy, Hormone Replacement) 03/2016 - 01/2003
4	Ovariectomy (Oophorectomy) 11/2016 - 04/2004